VACBF (Nykode Therapeutics AS) Shares Outstanding (Basic Average): 411.30 Mil (As of Mar. 2026)


VACBF Nykode Therapeutics AS VACBF
28 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Shares Outstanding (Basic Average)?

Nykode Therapeutics AS VACBF 28 Shares Outstanding (Basic Average) is 411.30 Mil as of Mar. 2026. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Nykode Therapeutics AS's average basic shares outstanding for the quarter that ended in Mar. 2026 was 411.30 Mil.

Nykode Therapeutics AS  (OTCPK:VACBF) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Nykode Therapeutics AS Shares Outstanding (Basic Average) Related Terms

Nykode Therapeutics AS Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Shares Outstanding (Basic Average) Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only 286.35 290.12 300.52 326.55 326.55

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 326.55 326.55 366.00 399.85 411.30
VACBF
28GF Score
Nykode Therapeutics AS VACBF
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 411.30 Mil mean?
Nykode Therapeutics AS (VACBF) has a Shares Outstanding (Basic Average) of 411.30 Mil as of Mar. 2026. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Shares Outstanding (Basic Average) too high?
Nykode Therapeutics AS's current Shares Outstanding (Basic Average) is 411.30 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Shares Outstanding (Basic Average) compare to VRTX and REGN?
Nykode Therapeutics AS's Shares Outstanding (Basic Average) of 411.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Shares Outstanding (Basic Average) is 411.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.3% below its estimated fair value. The current Shares Outstanding (Basic Average) is 411.30 Mil. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Shares Outstanding (Basic Average) is 411.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.3% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Shares Outstanding (Basic Average): 411.30 Mil
  • GF Value™: $0.76 vs. price of $0.32 (57.3% below fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score

Get the complete analysis for VACBF

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value